%0 Thesis
%A Cañas Barrios, Daniela
%8 2023-10-27
%U http://hdl.handle.net/10818/59203
%X Community-acquired pneumonia (CAP) continues to be one of the leading causes of 
mortality worldwide, and it is the leading cause of death from infectious diseases (1). 
Annually, approximately 4,000 new cases of this condition are reported, of which 
between 20% and 42% of patients require in hospital managment and treatment. In 
addition, patients with severe CAP (SCAP)a are a highlighted group due to their higher 
mortality risk. They represent between 10% and 30% of the total population with CAP 
and usually require admission to the intensive care unit (ICU)(2). Therefore, it is critical 
to provide an adequate and timely treatment to these patients in order to reduce 
mortality rates. According to Ceccato et al. (3), conventional antibiotic therapy has 
some limitations, because these drugs do not directly modulate the inflammatory 
response. Furthermore, it is known that between 10% - 15% of hospitalized patients 
with CAP may not respond to antibiotic therapy due to factors such as the etiological 
microorganism, the severity of CAP and characteristics of the host (4); hence, the use 
of corticosteroids has been studied as a biologically plausible treatment option due to 
its mechanism of action.
%I Universidad de La Sabana
%T Effect of corticosteroids in critical patients with severe community-acquired pneumonia: emulation of a clinical trial
%~ Intellectum